<?xml version="1.0" encoding="UTF-8"?>
<p>Several drugs have been trialled on SARS-CoV-2 patients such as hydroxychloroquine and azithromycin with ambiguous results on the virus but possibly exacerbating liver injury [
 <xref rid="B34-pathogens-09-00430" ref-type="bibr">34</xref>]. This ambiguity leads to many questions involving the management of SARS-CoV-2 and pre-existing liver disease.
</p>
